Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical distributor McKesson (MCK 2.33%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at McKesson and see what CAPS investors are saying about the stock right now.
McKesson facts
|
Headquarters (Founded) |
San Francisco (1833) |
|
Market Cap |
$24.5 billion |
|
Industry |
Health-care distributors |
|
Trailing-12-Month Revenue |
$123.2 billion |
|
Management |
Chairman/CEO John Hammergren |
|
Return on Equity (Average, Past 3 Years) |
18.8% |
|
Cash/Debt |
$2.8 billion / $3.6 billion |
|
Dividend Yield |
0.8% |
|
Competitors |
AmerisourceBergen (ABC +2.10%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 619 members who have rated McKesson believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, brenoboyle, touched on a few of the tailwinds working in McKesson's favor: "Increasing coverage for prescription drug benefits, very shareholder friendly consistent repurchases, patent cliff for pharma will led to more generic prescription drug coverage for which [McKesson] has higher margins."
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
